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822Objective: Our hypothesis is that cardiac retransplantation is a viable option for selected recipients. Furthermore,
in some patients multiple retransplantations are reasonable.
Methods:We studied 23 patients who had all received an elective second, third, or fourth cardiac transplant over
a 25-year period. Comparisons were made with 792 primary transplantations. Subsequent retransplantations
(third and fourth time) were elective and included in the evaluation.
Results: Twenty-three patients electively received a second, 4 a third, and 1 a fourth transplant for coronary
vasculopathy or chronic graft failure. Sixteen (70%) patientsweremen, and 7 (30%)werewomen.Median survival
in years for primary cardiac recipientswas 10.7 years; for a second transplantation,median survival from the date of
retransplantationwas 9.3 years. Average age at the time of first transplantationwas 47.8 years, and it was 44.3 years
at the time of second transplantation. No significant differencewas noted inKaplan–Meier survival curves between
patients undergoing primary transplantation and elective retransplantation. Survival at 1 year for patients undergo-
ing afirst transplantationwas 88.8%, and itwas 81.8% for patients undergoing retransplantation. Patient survival at
10 years was nearly identical for patients undergoing first-time transplantation and those undergoing retransplan-
tation (58%). All 5 third- and fourth-time transplant recipients survived.
Conclusions:Cardiac retransplantation is a reasonable option for elective recipients with coronary vasculopathy
or chronic graft failure. Survival for groups undergoing primary transplantation and retransplantation is similar.
Careful selection of this small group of cardiac recipients (3% of the total) might be the key to success. (J Thorac
Cardiovasc Surg 2011;141:822-7)Since the first successful cardiac retransplantation in 1974,1
multiple reports have summarized experiences2-7 with
adults and children. Nevertheless, the topic has remained
controversial for more than 3 decades, but there are some
accepted guidelines. Retransplantation is done in only 2%
to 3% of primary transplant recipients and is reserved for
‘‘good’’ or ‘‘selected’’ patients who undergo transplantation
electively at 6 months or more after the first transplantation.
Most of these patients have advanced coronary vasculop-
athy at the time of retransplantation. In this patient group
short- and long-term survival has been indistinguishable
from that after primary transplantation.2
Cardiac recipients with intractable rejection or graft fail-
ure in the first days to 6 months after initial transplantation
have had much higher mortality rates8 with retransplanta-
tion. Most authors have discouraged retransplantation in
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The Journal of Thoracic and Cardiovascular SurgOf historical interest, the first successful cardiac retrans-
plantation was in a 13-year-old with intractable rejection of
his first transplanted heart.1 He was unstable for nearly 60
days before having a second transplantation, followed by
survival for more than 10 years. This was in the era of pred-
nisone, azathioprine, and rabbit antithymocyte globulin
therapy.
We report our experiencewith retransplantation since 1981.MATERIALS AND METHODS
We received human subject institutional review board approval for a ret-
rospective chart review. Awaiver of consent was also approved for the con-
duct of this study. Chart reviews of the patients undergoing retransplantation
documented demographic and etiologic information, as well as the patient’s
condition, hemodynamics, reason for retransplantation, and complications,
including infection, rejection, and end-organ failure. One-year evaluation
studies, complications of patients undergoing multiple retransplantation,
and survival durations after second, third, and fourth transplantations were
also recorded. All primary cardiac transplant recipients at our institution
served as the control group for Kaplan–Meier curves. Retransplantation sur-
vival curves included all retransplantations (ie, first through third). Tests for
equality of these curves were performedwith the log-rank test. Time to event
analyses included comparisons of patients undergoing primary transplanta-
tion versus patients undergoing retransplantation for patient survival, graft
survival, rejection, renal failure, and leukopenia. Patientswho receiveda third
transplant and the patient who received a fourth transplant were included in
these analyses. Immunosuppresion changed over the course of this experi-
ence from reliance on cyclosporine and azathioprine in addition to steroid
to more use of tacrolimus and mycophenylate mofetil and steroids. We did
not have a special protocol in these patients. All patients undergoingery c March 2011
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to sirolimus in an attempt to prevent graft coronary vasculopathy. Recently,
all of our patients have had baseline coronary arteriographic and intravascu-
lar ultrasound studies at 3months andwere then followed yearly for the first 4
to 5 years; thus we did not have a special follow-up protocol in place for pa-
tients undergoing retransplantation.
Retransplant recipient selection was similar to initial selection. Patients
were excluded for obesity (body mass index,35 kg/m2), chronic renal in-
sufficiency (creatinine,>1.5 mg/dL; glomerular filtration rate,<35 mL/
min), a history of noncompliance, any substance abuse or smoking, any
life-threatening systemic disease, and poor general condition.
Listing for retransplantation was done exactly as it was for patients un-
dergoing primary transplantation. Once listed, the probability of transplan-
tation was not different from that of the primary transplant candidates. The
time on the waiting list thus was a function of accumulated waiting time,
blood type, and United Network for Organ Sharing status. Twelve of these
patients were status IB receiving inotropic support, 9 were waiting for their
first retransplantation (second transplantation), and 3 were waiting for their
second retransplantation (third transplantation). Waiting times have
changed over the past 25 years, but in general, patients with blood types
O and A in United Network for Organ Sharing status IB have waited for
4 months to 1 year, and those in status II have waited for more than 1
year. Those with blood types B and AB have had shorter waiting times.
Our patients followed the same trends. Donor selection was no different
than for primary transplant recipients.
RESULTS
From March 1979 to September 2009, we performed 844
cardiac transplantations. Twenty-six (3%) were retransplan-
tations. Three patients receiving a second transplant were not
included in our evaluation because they were emergency, to-
tal artificial heart, bridge to transplantation patients followed
by emergency second transplantations. These 3 patients did
not follow the standard evaluation, listing, and protocol be-
fore their retransplantation and thus were excluded from
our study. One of those survived 9 years, and the other 2
died in less than 30 days.
We have evaluated 23 consecutive patients who had a total
of 51 transplantations: 23 primary transplantations, 23 sec-
ond transplantations, 4 third transplantations, and 1 fourth
transplantation. Our first cardiac retransplantation was done
in 1984. All retransplant recipients in this report, with one ex-
ception, had elective procedures. That exceptionwas a patient
who, at another institution, received his second transplant on
an emergency basis 5 days after the first and then, 4 years
later, received a third transplant electively at our center. There
were 16male and 7 female patients ranging in age at the time
of second transplantation from 8 to 64 years (mean, 42.4 
15.9 years), including 4 pediatric patients who were aged 8
to 18 years. Eighteen were white, 4 were Hispanic, and 1
was Asian. Blood groups were as follows: A, 15 patients;
O, 4 patients; B, 3 patients; andAB, 1 patient. Primary causes
that resulted in heart failure and the initial transplantation in-
cluded 9 ischemic, 7 dilated, 3 congenital, 3 peripartum, and
1 congenital.Before the initial heart transplantation, transpul-
monary gradients mean values were less than 12mmHg, and
pulmonary vascular resistance was less than 3 Wood units.
Fourteen had positive cytomegaloviral serologies.The Journal of Thoracic and CaIndications for second transplantation included coronary
vasculopathy in 21 patients, restrictive cardiomyopathy in
1 patient, and chronic graft failure in 1 patient. There was
1 patient who underwent retransplantation at another hospital
at 5 days. The remainder all underwent retransplantation at
our center from1.92 to 10.4 years after the primary transplan-
tation (mean, 5.8  4 years; median, 4.5 years). Preretrans-
plantation hemodynamics were generally those of patients
with deterioration after the first transplantation from diffuse
coronary vasculopathy. Twelvewere receiving inotropic sup-
port with dobutamine (n¼ 9), milrinone (n¼ 2), and norepi-
nephrine (n¼ 1). Fivewere diabetic. On preretransplantation
catheterization,mean pressures were as follows: right atrium,
10 mm Hg; pulmonary artery, 30/20 mm Hg; pulmonary
artery wedge pressure, 18 mm Hg; and cardiac output,
4.0 L/min. Left ventricular ejection fraction determined by
means of echocardiography averaged 32%. New York Heart
Association functional class averaged 3.0.
On 1-year follow-up coronary angiograms after the second
transplantation, only 1 patient had any coronary disease pa-
thology. This was a thrombotic occlusion of the left anterior
descending artery secondary to the catheterization that re-
solved with stenting but did cause a nonfatal myocardial in-
farction, and the patient died about 1 month later. Left
ventricular ejection fractions were also normal, with a mean
valueof 59% 7%. Survival after the second transplantation
ranged from 2.5 months to 23 years (mean, 5.6  5.6 years;
median, 5.5 years). During that period of 128 patient-years,
there were 21 treated infections (0.16 per patient-year). All
but 1 patient was taking tacrolimus. Sevenwere takingmyco-
phenylate, with the remainder taking azathioprine, and all
were receiving low-dose prednisone.
Four patients had third transplantations 2.8 to 11.5 years
after the second transplantation (mean, 5.9 3.9 years). In-
dications included severe coronary vasculopathy (n ¼ 3)
and heart failure (n ¼ 1) after an episode of acute rejection.
They have survived for a mean duration of 9  1.6 years
(range, 3.8–11.5 years) after the third transplantation. Three
of the four patients died: 1 died from coronary vasculop-
athy, 1 experienced sudden death, and 1 died from pulmo-
nary varicella. The fourth of these patients had a fourth
transplantation for severe coronary vasculopathy 10.5 years
after his third transplantation. He remains alive and in New
York Heart Association functional class I and is currently on
dialysis. He is 5.5 years after the fourth transplantation and
23.7 years after his first transplantation at age 11 years. He
is being evaluated for a kidney transplantation.
Thus far, the mean survival time of all retransplant recipi-
ents has been 13.6  6 years (range, 2.6–24.9 years). Nine
(39%) of the patients are still surviving at 3.6 to 24.9 years
(mean, 17.3  7.6 years) after the initial transplantation.
The median survival has been 9.3 years (Figure 1), and the
Kaplan–Meier survival curves comparing our primary trans-
plantation group with the retransplantation group are notrdiovascular Surgery c Volume 141, Number 3 823
FIGURE 1. Patient survival: 818 patients undergoing primary transplanta-
tion are shown in blue, and 23 patients undergoing elective retransplantation
are shown in green. Tx, Transplantation.
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1 summarizes the currently living patients with respect to to-
tal survival, number of transplantations, coronary anatomy
studies (all but 1 have had recent angiographic and intravas-
cular ultrasound studies), hemodynamic data, and echocar-
diographic left ventricular ejection fraction.
Rejection was significantly less in the primary transplan-
tation group, with a freedom from rejection at 1 year afterTABLE 1. Current survivors showing total time of survival, number of tra
Patient
no.
Total
survival (y)
No. of
transplantations
Years since second,
third, and fourth
transplantations
Coronary
arteries
1 3.66 2 2.16 Normal
2 8.75 2 2.83 Normal
3 13.3 2 4 Normal
4 14.66 2 3.83 Normal
5 20.16 2 15.08 Normal
6 22.5 2 16.7 Normal
7 23.7 2 10.25 Normal
8 23.7 4 2.75, 10.5, 5.5 Normal
9 24.9 2 23 Normal
(>10 y ago
All catheterizations except for patient 9 (performed in 1989) and patient 7 (performed in 200
coronary artery anatomy; IVUS, intravascular ultrasound standard to examine mid–left a
pulmonary artery; PAW, pulmonary artery wedge pressure; LVEF, left ventricular ejection
824 The Journal of Thoracic and Cardiovascular Surgtransplantation of 46% compared with the retransplantation
group’s freedom from rejection of 18% (P ¼ .02, log-rank
test; Figure 2).
Renal dysfunction, defined as a serum creatinine level of
greater than 2.25 mg/dL, was significantly more common in
the retransplantation group. At 1 and 5 years after transplan-
tation, freedom from renal dysfunction was 69% (n ¼ 510)
and 50% (n ¼ 255) for primary recipients and 49%
(n ¼ 10) and 30% (n ¼ 4) for retransplant recipients, re-
spectively. Kaplan–Meier curves for freedom from renal
dysfunction (Figure 3) demonstrated significantly less renal
failure in the primary transplantation group than in the re-
transplantation group (P ¼ .03, log-rank test).
White blood cell counts over the years were also lower
for the retransplant recipients. We defined leukopenia as
any white blood cell count of less than 3500/mL. The pri-
mary recipients had significantly fewer leukopenic epi-
sodes than the retransplant recipients (P ¼ .02, log-rank
test) (Figure 4).
Fourteen patients have died at 0.04 to 16 years after re-
transplantation, including 3 having undergone 3 transplan-
tations (Table 2). Total survival in these patients ranged
from 2.59 to 24.75 years (mean, 11.3 years). Causes of
death are shown in Table 2 and include 5 episodes of sud-
den death (1 confirmed secondary to coronary vasculop-
athy and 1 iatrogenic), 4 infections, 2 strokes, and 1 case
each of lung cancer, multiple organ failure, and renal fail-
ure. Four patients died within 6 months of retransplanta-
tion: 3 from infection and 1 from multiple organ failure.
Of the remaining 10 deaths, 5 were sudden, 2 were strokes,
1 was from cancer, 1 was from renal failure, and 1 was
from viral pneumonia.DISCUSSION
The 2010 International Society for Heart & Lung Trans-
plantation Registry reports9 the following causes of deathnsplants, and time since the second, third, and fourth transplantations
IVUS
RA
(mm Hg)
PA
(mm Hg)
PAW
(mm Hg)
LVEF by
echocardiography
1 mm LAD 12 35/20 5 44
Normal 2 18/8 6 60
0.5 mm LAD 12 47/22 24 65
0.5 mm LAD 7 38/18 18 55
1 mm LAD 14 40/24 20 45
1–1.5 mm LAD 28/16 8 65
Normal 5 16/10 9 70
Normal 4 20/12 6 55
)
1 mm LAD
(>10 y ago)
4 19/12 10 78
5), were completed in the past 2 years.Coronary arteries, Angiographic assessment of
nterior descending coronary artery for subintimal thickening; RA, right atrium; PA,
fraction; LAD, left anterior descending coronary artery.
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FIGURE 2. Freedom from rejection: patients undergoing primary trans-
plantation are shown in blue, and patients undergoing retransplantation
are shown in green. Tx, Transplantation; ReTx, retransplantation.
FIGURE 3. Freedom from serum creatinine level of greater than 2.25 ml/
dL for primary transplant recipients (blue) and retransplant recipients
(green). Tx, Transplantation; ReTx, retransplantation.
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ages of total deaths for recipients surviving for more than 10
years: coronary vasculopathy, 14%; infection, 9.8%; cere-
brovascular, 4.5%; and malignancy, 18%.
In a recent single-center review of cardiac retransplanta-
tion,3 postretransplantation survival was found to be signif-
icantly lower than in primary transplant recipients. From the
same institution, a follow-up study found a higher incidence
of comorbidities in retransplant recipients.9 Among their 23
deaths, 34% were from malignancy, 26% were from infec-
tion, 13% were from rejection, 17% were from sudden
death or coronary vasculopathy, and 4% were from postop-
erative bleeding. The predominant causes in their series and
in ours were infection and coronary vasculopathy/sudden
death. They saw more malignancy.
Our experience points to 2 types of postretransplantation
deaths: those that occurred at less than 6 months related to
infection (n ¼ 3) and multiple organ failure (n ¼ 1) and
those that occurred later related to coronary vasculopathy
(n ¼ 4) and chronic posttransplantation issues (n ¼ 6).
Two of the sudden deaths were at just over a year after re-
transplantation, and the other 3 sudden deaths were more
than 5 years after retransplantation. The other causes of
late death (ie, stroke, renal failure, cancer, and opportunistic
infection) are also predictable causes of late mortality in
a primary transplantation population.The Journal of Thoracic and CaNearly all patients selected for retransplantation had se-
vere coronary vasculopathy, but the incidence of coronary
vasculopathy after retransplantation was not as impressive
as expected. Sudden death, a presumed manifestation of
coronary vasculopathy, did cause 36% of the deaths. One
of these was iatrogenic, and only 1 was proved coronary
vasculopathy. Given the preponderance of coronary vascul-
opathy before retransplantation, we would have expected
more after transplantation. This is particularly true when
we look at Table 1, which shows that in the 9 surviving pa-
tients there was no epicardial vessel disease and no critical
coronary disease as defined by intravascular ultrasound late
after retransplantation. Also, the 1-year coronary angio-
grams after retransplantation did not find significant coro-
nary vasculopathy in any of our patients. One patient had
iatrogenic disease and left anterior descending coronary ar-
tery dissection from catheterization followed by stenting
and died suddenly about 1 month later. The second sudden
death at just over 1 year was in the patient who did not have
a coronary angiogram. Sudden death and graft coronary dis-
ease might not be as strong as we thought.
There were no deaths from rejection. Our approach has
been to perform retransplantation in chronically immuno-
suppressed patients and not escalate therapy. We have at-
tempted after the first 1 to 2 weeks to return all of these
patients to the same level of immunosuppresion they wererdiovascular Surgery c Volume 141, Number 3 825
FIGURE 4. Freedom from leukopenia (<3500 white blood cells/mL) for
primary transplant recipients (blue) and retransplant recipients (green). Tx,
Transplantation; ReTx, retransplantation.
TABLE 2. Nonsurvivors showing total years of survival after first transplantation, number of transplantations, times of survival after the second
and third transplantations, and causes of death
Patient no.
Total survival
time (y)
No. of
transplantations
Survival after second and
third transplantation (y) Cause of death
1 2.59 2 0.17 Aspergillus species–induced pneumonia
2 4.42 2 1.17 Sudden
3 5 2 0.5 Sepsis
4 6.72 2 0.04 Multiorgan failure
5 7.61 2 0.19 Mediastinitis
6 8.08 2 5.75 Sudden
7 8.75 2 2.83 Stroke
8 12.5 2 9.25 Lung cancer
9 13 2 10.75 Cerebral hemorrhage
10 14.34 2 3.92 Renal failure
11 15 3 3.38, 11.5 Sudden
12 17.16 2 1.16 Sudden iatrogenic coronary disease
13 18.42 3 11.5, 3.75 Varicella pneumonia
14 24.75 3 10.5, 5.5 Coronary vasculopathy
There were 5 sudden deaths, 4 presumed to be from coronary vasculopathy. One of these was confirmed by postmortem examination.
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crossover to mycophenalate and tacrolimus. Only 1 of these
patients was started on sirolimus, and that was for decreased
renal function. Our finding that rejection in this retransplan-
tation group was increased raises questions regarding opti-
mal immunosuppresion. We have not changed our approach
of lower-level immunosuppresion in retransplantation from
what would be used in primary transplantations because we
have seen no fatal rejections, and we believe we might have
avoided the previously reported higher incidences of infec-
tion and malignancy.9
The mean survival for our retransplant recipients was
13.6 years for the entire group and 17.3 years for the current
survivors. Both of these numbers compare favorably with
the International Society for Heart & Lung Transplantation
Registry. The 4 patients receiving a third transplant had ad-
ditional survival of 3.8 to 11.5 years, and 1 patient had
a fourth transplant 10.5 years after his third transplantation
and is still alive 5.5 years after the fourth transplantation and
23.7 years since the first transplantation. We think this expe-
rience supports the concept of multiple transplantations.
Similar patient survival curves (Figure 1) for patients under-
going primary transplantation and retransplantation also
suggest that retransplantation is a viable option. Years of
life are gained, and donor hearts are not wasted.
Comparisons of complications for rejection, renal dysfunc-
tion, and leukopenia were unfavorable for retransplant recip-
ients. Freedom from rejection at 1 year after transplantation
was 46% for patients undergoing primary transplantation
and 18% for patients undergoing retransplantation. Class
III renal dysfunction (serum creatinine,>2.25 mg/dL) was
significantly less in the patients undergoing primary trans-
plantations, as was leukopenia (white blood cell count,
<3500/mL). Yet in the face of more rejection episodes,
more renal dysfunction, and lower white blood cell counts,826 The Journal of Thoracic and Cardiovascular Surgthe retransplant recipients did not have lower probability of
survival.
We believe, on the basis of this experience, that in stable
selected cardiac recipients, retransplantation is reasonable.
Our approach is to evaluate patients for retransplantation
using the same criteria we would use for primary recipients.ery c March 2011
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a stringent application of basic principles of selection. We
have avoided patients with morbid obesity, end-organ dys-
function, substance abuse, smoking, poor compliance,
life-threatening systemic disease, and poor general condi-
tion. Finally, as a result of poor outcomes, we have avoided
emergency retransplantation shortly after total artificial
heart implantation for the past 20 years.
We were surprised that survival in these ‘‘stable retrans-
plant recipients’’ was not different than in primary patients
in our institution, even though the incidences of rejection,
renal dysfunction, and leukopenia were higher. Also, for
a group who had coronary vasculopathy as the primary rea-
son for retransplantation, the incidence of proved coronary
vasculopathy was less than expected.
If one accepts that the retransplantations were indicated
and reasonably timed in this retrospective review of 23 cases,
then the result has been to add years to a patient’s life. An av-
erage of 5.6 years of survival per patient was added by the
second transplantations and 9.2 patient survival years by
the third transplantations. The only fourth transplant recipi-
ent has thus far lived an additional 5.5 years. These numbersThe Journal of Thoracic and Casupport a recommendation for performing retransplantation
in carefully selected cardiac transplant recipients.
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